NL-OMON24928
Not yet recruiting
Not Applicable
Oncolytic adenovirus therapy as an adjuvant treatment for localised prostate cancer.
Overview
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Erasmus MC
- Enrollment
- 18
Overview
Brief Summary
/A
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1\. Men 35\-70 years old scheduled to undergo radical prostatectomy in Erasmus MC
- •2\. Histologically proven adenocarcinoma of the prostate
Exclusion Criteria
- •1\. Patients with \>\= 20% risk on lymph node involvement according to the Memorial Sloan\-Kettering Cancer Centre (MSKCC) Prostate Cancer Prediction Tool for pre\-treatment risk assessment. This tool is available at http://www.mskcc.org/mskcc/html/10088\.cfm
- •2\. Prior androgen ablation hormonal therapy (except treatment with finasteride \- if discontinued \> 3 months prior to inclusion in current protocol)
Investigators
Similar Trials
Completed
Not Applicable
Oncolytic adenovirus therapy as an adjuvant treatment for localised prostate cancer.prostate cancerProstate carcinoma1003859710036958NL-OMON43563Erasmus MC, Universitair Medisch Centrum Rotterdam18
Completed
Not Applicable
Adoptive immunotherapy for adenovirus (AdV)-associated complications post transplantatioISRCTN14732774Charité - University Medicine Berlin (Germany)306
Recruiting
Phase 1
OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder CancerNon-muscle-invasive Bladder CancerNCT05232136Binhui Biopharmaceutical Co., Ltd.30
Withdrawn
Phase 1
Virus-specific ImmunoTherapy Following Allogeneic Stem Cell TransplantationCytomegalovirus InfectionAdenovirus InfectionNCT02702427St. Anna Kinderkrebsforschung
Recruiting
Not Applicable
Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural MesotheliomaMalignant Pleural Mesothelioma, AdvancedNCT06031636Tianjin Medical University Second Hospital15